

Jurisdiction Specific Medicare Part B Dextenza

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Dextenza	dexamethasone ophthalmic insert

Covered uses

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- Ocular Inflammation and Pain Following Ophthalmic Surgery
- Itching Associated with Allergic Conjunctivitis

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

Exclusions

Coverage will not be provided for members with any of the following exclusions:

- Active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella
- Mycobacterial infections of the eye
- Fungal diseases of the eye
- Dacryocystitis

Coverage Criteria

Ocular Inflammation and Pain Following Ophthalmic Surgery

Authorization of 3 months may be granted for treatment of ocular inflammation and pain following ophthalmic surgery.

Itching Associated with Allergic Conjunctivitis

Authorization of 3 months may be granted for the treatment of itching associated with allergic conjunctivitis.

References

1. Dexamethasone Intracanalicular Ophthalmic Insert (Dextenza®) LCD (L38792) Version R1. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed November 29, 2023.
2. Billing and Coding: Dexamethasone Intracanalicular Ophthalmic Insert (Dextenza®) (A58392) Version R2. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed November 29, 2023.
3. Dextenza [package insert]. Bedford, MA: Ocular Therapeutix, Inc; October 2021.